JP2023182689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023182689A5 JP2023182689A5 JP2023169033A JP2023169033A JP2023182689A5 JP 2023182689 A5 JP2023182689 A5 JP 2023182689A5 JP 2023169033 A JP2023169033 A JP 2023169033A JP 2023169033 A JP2023169033 A JP 2023169033A JP 2023182689 A5 JP2023182689 A5 JP 2023182689A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid number
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021072429 | 2021-04-22 | ||
| JP2021072429 | 2021-04-22 | ||
| PCT/JP2022/018350 WO2022224997A1 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
| JP2023515503A JP7365654B2 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515503A Division JP7365654B2 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023182689A JP2023182689A (ja) | 2023-12-26 |
| JP2023182689A5 true JP2023182689A5 (https=) | 2025-04-28 |
| JP7822576B2 JP7822576B2 (ja) | 2026-03-03 |
Family
ID=83722348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515503A Active JP7365654B2 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
| JP2023169033A Active JP7822576B2 (ja) | 2021-04-22 | 2023-09-29 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515503A Active JP7365654B2 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12227586B2 (https=) |
| EP (1) | EP4327823A4 (https=) |
| JP (2) | JP7365654B2 (https=) |
| KR (1) | KR20230171465A (https=) |
| CN (1) | CN117222672A (https=) |
| AR (1) | AR125398A1 (https=) |
| AU (1) | AU2022262542A1 (https=) |
| CA (1) | CA3217637A1 (https=) |
| CL (1) | CL2023003100A1 (https=) |
| CO (1) | CO2023015630A2 (https=) |
| CR (1) | CR20230490A (https=) |
| DO (2) | DOP2023000230A (https=) |
| EC (1) | ECSP23087918A (https=) |
| IL (1) | IL307744A (https=) |
| JO (1) | JOP20230261A1 (https=) |
| MX (1) | MX2023012432A (https=) |
| PE (1) | PE20241357A1 (https=) |
| SA (1) | SA523451235B1 (https=) |
| TW (1) | TW202309083A (https=) |
| WO (1) | WO2022224997A1 (https=) |
| ZA (1) | ZA202310292B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4524248A1 (en) | 2022-05-12 | 2025-03-19 | Astellas Pharma, Inc. | Anti-taa/anti-cd3 multispecific antibody |
| EP4606384A1 (en) * | 2022-10-19 | 2025-08-27 | Astellas Pharma, Inc. | Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment |
| WO2026042803A1 (ja) * | 2024-08-21 | 2026-02-26 | アステラス製薬株式会社 | がん治療におけるプラチナ系薬剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| KR100999844B1 (ko) | 2006-07-19 | 2010-12-13 | 네오벌브 테크놀러지스 인크 | 고효율 방열 모듈을 구비한 고출력 ｌｅｄ 조명장치 |
| WO2008114733A1 (ja) | 2007-03-16 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-4抗体 |
| EP2346994B1 (en) | 2008-09-30 | 2022-02-16 | Ablexis, LLC | Knock-in mice for the production of chimeric antibodies |
| JP2014193853A (ja) | 2013-03-01 | 2014-10-09 | Japan Health Sciences Foundation | 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー |
| CN118440206A (zh) | 2014-04-07 | 2024-08-06 | 中外制药株式会社 | 免疫活化抗原结合分子 |
| KR20170138574A (ko) | 2015-05-04 | 2017-12-15 | 피어이스 파마슈티컬즈 게엠베하 | 항암 융합 폴리펩타이드 |
| WO2019048040A1 (en) | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
| US20210054076A1 (en) | 2018-01-05 | 2021-02-25 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| AU2019235900B2 (en) * | 2018-03-14 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Engineered cells, T cell immune modulating antibodies and methods for using the same |
| BR112021000282A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a cd137 e ox40 |
-
2022
- 2022-04-21 KR KR1020237039211A patent/KR20230171465A/ko active Pending
- 2022-04-21 CA CA3217637A patent/CA3217637A1/en active Pending
- 2022-04-21 TW TW111115193A patent/TW202309083A/zh unknown
- 2022-04-21 WO PCT/JP2022/018350 patent/WO2022224997A1/ja not_active Ceased
- 2022-04-21 PE PE2023002906A patent/PE20241357A1/es unknown
- 2022-04-21 AU AU2022262542A patent/AU2022262542A1/en active Pending
- 2022-04-21 AR ARP220101032A patent/AR125398A1/es unknown
- 2022-04-21 EP EP22791768.9A patent/EP4327823A4/en active Pending
- 2022-04-21 CN CN202280029125.XA patent/CN117222672A/zh active Pending
- 2022-04-21 JP JP2023515503A patent/JP7365654B2/ja active Active
- 2022-04-21 CR CR20230490A patent/CR20230490A/es unknown
- 2022-04-21 US US18/556,606 patent/US12227586B2/en active Active
- 2022-04-21 MX MX2023012432A patent/MX2023012432A/es unknown
- 2022-04-21 IL IL307744A patent/IL307744A/en unknown
-
2023
- 2023-09-29 JP JP2023169033A patent/JP7822576B2/ja active Active
- 2023-10-18 CL CL2023003100A patent/CL2023003100A1/es unknown
- 2023-10-19 JO JOJO/P/2023/0261A patent/JOP20230261A1/ar unknown
- 2023-10-19 DO DO2023000230A patent/DOP2023000230A/es unknown
- 2023-10-22 SA SA523451235A patent/SA523451235B1/ar unknown
- 2023-11-03 ZA ZA2023/10292A patent/ZA202310292B/en unknown
- 2023-11-20 CO CONC2023/0015630A patent/CO2023015630A2/es unknown
- 2023-11-21 EC ECSENADI202387918A patent/ECSP23087918A/es unknown
-
2025
- 2025-01-14 US US19/020,859 patent/US20250154272A1/en active Pending
- 2025-09-09 DO DO2025000223A patent/DOP2025000223A/es unknown